|
|
|
|
|
|
|
|
|
|
media
....In a midstage study of 204 patients, rucaparib shrunk tumors in 32 of 39 patients with BRCA mutations. Four women in that group had their tumors disappear, known as a complete response. The study data was released Saturday at the American Society of Clinical Oncology’s meeting in Chicago.....
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.